Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2014 16:01 ET | Source: Receptos, Inc.

Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast

SAN DIEGO, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will...
October 27, 2014 16:01 ET | Source: Receptos, Inc.

Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis

– Study met primary efficacy and all secondary endpoints with statistical significance for patients on 1 mg dose after 8 weeks of treatment – – Safety data are consistent...
October 03, 2014 08:00 ET | Source: Receptos, Inc.

Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis

SAN DIEGO, Oct. 3, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
September 10, 2014 08:00 ET | Source: Receptos, Inc.

Receptos Announces Oral Podium Presentation at MS Boston 2014

Detailed Results of Positive Phase 2 Trial of RPC1063 in Relapsing Multiple Sclerosis to be Presented at Late Breaker Session on September 13, 2014 Company to Host Investor Call and Webcast on...
August 12, 2014 07:30 ET | Source: Receptos, Inc.

Receptos Reports Second Quarter 2014 Financial Results

Completes enrollment of Phase 2 trial of RPC1063 in Ulcerative Colitis; data expected in fourth quarter of 2014 Announces oral platform presentation of Phase 2 data for RPC1063 in Relapsing...
August 08, 2014 08:00 ET | Source: Receptos, Inc.

Receptos to Present at Wedbush PacGrow Life Sciences Conference

SAN DIEGO, Aug. 8, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
August 07, 2014 16:01 ET | Source: Receptos, Inc.

Receptos to Hold Second Quarter 2014 Financial Results Conference Call and Webcast

SAN DIEGO, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will...
July 29, 2014 08:00 ET | Source: Receptos, Inc.

Receptos Announces Appointment of Mary Szela and Richard Heyman, Ph.D. to Board of Directors

SAN DIEGO, July 29, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
June 24, 2014 09:34 ET | Source: Receptos, Inc.

Receptos Announces Closing of Underwritten Public Offering of Common Stock

SAN DIEGO, June 24, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
June 18, 2014 19:42 ET | Source: Receptos, Inc.

Receptos Announces Pricing of Underwritten Public Offering of Common Stock

SAN DIEGO, June 18, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...